Adjuvant Tamoxifen for 10 Years Better Than 5 Years in ER-Positive Breast Cancer

Article

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Click here to view the full-text version of this article.

Recent Videos
Gus Alva, MD | Credit: Gus Alva, MD
Gus Alva, MD | Credit: Gus Alva, MD
Gus Alva, MD | Credit: Gus Alva, MD
Gus Alva, MD | Credit: Gus Alva, MD
Gus Alva, MD | Credit: Gus Alva, MD
A panel of 5 experts on iron deficiency anemia
A panel of 5 experts on iron deficiency anemia
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
A panel of 5 experts on iron deficiency anemia
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
© 2024 MJH Life Sciences

All rights reserved.